| Ambrisentan and its role in the management of pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 19198697 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ambrisentan is the second selective endothelin-A receptor antagonist to be licensed in Europe, and the first in the United States, for the management of pulmonary arterial hypertension (PAH). It has been shown to be clinically effective in improving exercise tolerance and functional class. Furthermore, ambrisentan is well tolerated and associated with low rates of liver toxicity and minimal interactions with other medicines commonly used to treat PAH. Overall, current data support a role for ambrisentan in the management of PAH. However, the results of longer-term follow-up studies are still required to fully assess efficacy and safety. |
| | |
Authors:
|
Iain M Macintyre; Neeraj Dhaun; Jane Goddard; David J Webb |
Related Documents
:
|
1565817 - Changes in spirometry during consecutive admissions for infective pulmonary exacerbatio... 15136907 - Restrictive ventilatory impairment and arterial oxygenation characterize rest and exerc... 1768827 - Preoperative cardiopulmonary exercise testing: determining the limit to exercise and pr... 11082387 - Cardiac exercise hemodynamics late after partial left ventriculectomy. 11317177 - Effects of pefloxacin on urinary and salivary concentrations of isoniazid in six health... 8857497 - Skeletal muscle hypoperfusion during recovery from maximal supine bicycle exercise in p... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs of today (Barcelona, Spain : 1998) Volume: 44 ISSN: 1699-3993 ISO Abbreviation: Drugs Today Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2009-02-09 Completed Date: 2009-05-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160518 Medline TA: Drugs Today (Barc) Country: Spain |
Other Details:
|
Languages: eng Pagination: 875-85 Citation Subset: IM |
Copyright Information:
|
Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved. |
Affiliation:
|
Clinical Pharmacology Unit, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK. imacint2@staffmail.ed.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / therapeutic use* Clinical Trials as Topic Drug Interactions Follow-Up Studies Humans Hypertension, Pulmonary / drug therapy*, physiopathology Phenylpropionates / pharmacokinetics, therapeutic use*, toxicity Pyridazines / pharmacokinetics, therapeutic use*, toxicity Receptor, Endothelin A / antagonists & inhibitors*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Phenylpropionates; 0/Pyridazines; 0/Receptor, Endothelin A; 177036-94-1/ambrisentan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pediatric Asthma and Problems in Attention, Concentration, and Impulsivity: Disruption of the Family...
Next Document: Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia.